Olaparib plus abiraterone in metastatic castration-resistant prostate cancer
16604
post-template-default,single,single-post,postid-16604,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Olaparib plus abiraterone in metastatic castration-resistant prostate cancer

Home > Blogs  > Olaparib plus abiraterone in metastatic castration-resistant prostate cancer

30 Sep Olaparib plus abiraterone in metastatic castration-resistant prostate cancer

Posted at 12:02h in Blogs by

In the phase 3 PROpel trial, a significant improvement in overall survival is observed for olaparib with abiraterone compared to placebo with abiraterone in patients with mCRPC.  The improvement observed was primarily attributable to patients with BRCA mutation. ( Ref: Saad F, et al. Lancet Oncol. Sep 12, 2023)

#oncologyresearch #clinicalresearch #clinicaldevelopment

No Comments

Sorry, the comment form is closed at this time.